Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Vascular Calcification 1Neoplasm Metastasis 1Kidney Diseases 1Hyperparathyroidism 1Chronic Kidney Disease-Mineral and Bone Disorder 1Bone Diseases 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × etelcalcetide hydrochloride × Clear all
NCT03960437 2023-09-21

Parsabiv-MBD

Columbia University

Phase 2 Completed
22 enrolled 14 charts
GenitourinaryHead & Neck

Bone Diseases, Hyperparathyroidism, Kidney Diseases, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder, Vascular Calcification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡